Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study
Acta Oncol. 2024 Apr 9;63:164-168. doi: 10.2340/1651-226X.2024.35238.ABSTRACTBACKGROUND & PURPOSE: The COVID-19 pandemic posed a large challenge for healthcare systems across the world. Comprehensive data on the impact of the COVID-19 pandemic on incidence and mortality in lymphoma are lacking.PATIENTS/METHODS: Using data from the Swedish lymphoma register, we compare incidence and 1-year survival of lymphoma patients in Sweden before (2017-2019) and during the pandemic (2020 and 2021).RESULTS: Fewer patients were diagnosed with lymphomas during March-June 2020, but the annual incidence rates for 2020 and 2021 were similar...
Source: Acta Oncologica - April 9, 2024 Category: Cancer & Oncology Authors: Sara Ekberg Daniel Molin Simon Pahnke Fanny Bergstr öm Elsa Br ånvall Karin E Smedby Tove W ästerlid Source Type: research
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
CONCLUSION: In this pretreated cohort, osimertinib did not meet the prespecified end point threshold for efficacy, but responses were seen in a neuroendocrine carcinoma with an EGFR exon 20 S768T and exon 18 G719C mutation and an epithelial carcinoma with an EGFR D770_N771insSVD mutation. Osimertinib was well tolerated and had a safety profile consistent with previous studies.PMID:38591867 | DOI:10.1200/PO.23.00454 (Source: Ann Oncol)
Source: Ann Oncol - April 9, 2024 Category: Cancer & Oncology Authors: Monica F Chen Zihe Song Helena A Yu Lecia V Sequist Christine M Lovly Edith P Mitchell Jeffrey A Moscow Robert J Gray Victoria Wang Lisa M McShane Larry V Rubinstein David R Patton P Mickey Williams Stanley R Hamilton Yoshie Umemura James V Tricoli Barbar Source Type: research
Successful treatment of severe splenic lymphoma ‑associated hemophagocytic syndrome by splenectomy and subsequent chemotherapy: A case report
Oncol Lett. 2024 Mar 22;27(5):222. doi: 10.3892/ol.2024.14355. eCollection 2024 May.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) represents a fatal immunopathology derived from excessive inflammatory reactions. In particular, lymphoma-associated hemophagocytic syndrome (LAHS) is associated with a dismal prognosis. The current study presented a challenging case of splenic LAHS. A 71-year-old man presented with fatigue and anorexia. Laboratory test results revealed anemia, thrombocytopenia, lactate dehydrogenase elevation and markedly elevated levels of ferritin (6,210 ng/ml) and soluble interleukin 2 receptor (sIL-2R; 1...
Source: Oncology Letters - April 9, 2024 Category: Cancer & Oncology Authors: Hideyuki Masui Maki Shindo Yuta Inoue Maki Sugiyama Atsushi Ueda Takero Shindo Kae Okoshi Koichi Kinoshita Source Type: research
Improving resource utilization: Axillary lymph node core biopsy triaging for lymphoma
CONCLUSIONS: Our enterprise overused hematopathology resources in the evaluation of AxLNCB performed in the study period. Our process could improve from the application of a simple tool generated from this cohort to predict percent risk of the specimen containing hematologic malignancy using patient characteristics easily found via routine chart review.PMID:38591770 | DOI:10.1093/ajcp/aqae032 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Carl Dernell John Astle Abraham Bogachkov Shelly Reimer Anubha Wadhwa Shadie S Majidi Bethany Canales Julie M Jorns Source Type: research
A promising future of metal-N-heterocyclic carbene complexes in medicinal chemistry: The emerging bioorganometallic antitumor agents
Med Res Rev. 2024 Apr 9. doi: 10.1002/med.22039. Online ahead of print.ABSTRACTMetal complexes based on N-heterocyclic carbene (NHC) ligands have emerged as promising broad-spectrum antitumor agents in bioorganometallic medicinal chemistry. In recent decades, studies on cytotoxic metal-NHC complexes have yielded numerous compounds exhibiting superior cytotoxicity compared to cisplatin. Although the molecular mechanisms of these anticancer complexes are not fully understood, some potential targets and modes of action have been identified. However, a comprehensive review of their biological mechanisms is currently absent. In...
Source: Cell Research - April 9, 2024 Category: Cytology Authors: Qian Zhao Bo Han Cheng Peng Nan Zhang Wei Huang Gu He Jun-Long Li Source Type: research
Cistanche phenylethanoid glycosides induce apoptosis and pyroptosis in T-cell lymphoma
This study offers experimental support for the potential application of CPhGs in the treatment of TCL.PMID:38590417 | PMC:PMC10998756 | DOI:10.62347/GEZW9659 (Source: Cell Research)
Source: Cell Research - April 9, 2024 Category: Cytology Authors: Ying Tang Fangxin Zhao Xuan Zhang Yan Niu Xiulan Liu Renqiqige Bu Yunlong Ma Geyemuri Wu Beibei Li Hongxin Yang Jianqiang Wu Source Type: research
Misdiagnosis of lymphoma as vasculitis: A case report
This article describes a patient with NKTCL misdiagnosed as vasculitis who presented with sinusitis, abdominal pain, anorexia, and lung shadows, and also presented with eosinophilia, which was misdiagnosed as eosinophilic granuloma. The article describes the clinical features, diagnostic methods and differential diagnosis of lymphoma and highlights the importance of a multidisciplinary approach in accurate diagnosis and treatment. AbstractNK/T-cell lymphoma (NKTCL) is a highly aggressive malignant tumour with a very poor prognosis, which often poses diagnostic difficulties due to the non-specificity of its clinical present...
Source: Respirology Case Reports - April 9, 2024 Category: Respiratory Medicine Authors: Shushan Wei,
Haobin Hu,
Haoyue Helena Lan,
Na Li,
Qingling Zhang Tags: CASE REPORT Source Type: research
Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy
Patients with mature B cell malignancies such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL) are at risk of developing secondary immunodeficiency disease (SID) owing to the underlying disease process and the use of anti-cancer treatments with immunosuppressive effects.1 Patients with mature B cell malignancies and SID are susceptible to severe, recurrent, or persistent infections that result in substantial morbidity and increased mortality, as well as a considerable economic burden. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 9, 2024 Category: Hematology Authors: Joshua Richter, Matthew S. Davids, Colin Anderson-Smits, Marta Kamieniak, Kaili Ren, Michael Hull, Jasjit K. Multani, Drishti Shah, Csaba Siffel Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 8, 2024 Category: Nuclear Medicine Authors: Lars Kurch Regine Kluge Source Type: research
Erratum: CD31 promotes diffuse large B-cell lymphoma metastasis by upregulating OPN through the AKT pathway and inhibiting CD8+ T cells through the mTOR pathway
Am J Transl Res. 2024 Mar 15;16(3):1036. doi: 10.62347/SBSI1515. eCollection 2024.ABSTRACT[This corrects the article on p. 2656 in vol. 15, PMID: 37193155.].PMID:38586108 | PMC:PMC10994810 | DOI:10.62347/SBSI1515 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Zhengchang He Shaoxian Shen Yuyao Yi Lingli Ren Huan Tao Fujue Wang Yongqian Jia Source Type: research
Exploring the molecular mechanisms between lymphoma and myelofibrosis
Am J Transl Res. 2024 Mar 15;16(3):730-737. doi: 10.62347/NWJO7078. eCollection 2024.ABSTRACTLymphoma is a heterogeneous malignant tumor with an increasing annual incidence. As the lymphoma progresses, bone marrow (BM) invasion gradually appears. Myelofibrosis (MF) can accompany a variety of hematological malignancies, including lymphoma, and multiple myeloma. The prognosis of lymphoma patients with myelofibrosis is poor, and a fundamental reason is that there are few studies on the correlation and pathogenesis of the two diseases. In this review, we examine the potential pathogenesis and the correlation of the two disease...
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Jun-Nuan Wang Yan Li Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 8, 2024 Category: Nuclear Medicine Authors: Lars Kurch Regine Kluge Source Type: research
Erratum: CD31 promotes diffuse large B-cell lymphoma metastasis by upregulating OPN through the AKT pathway and inhibiting CD8+ T cells through the mTOR pathway
Am J Transl Res. 2024 Mar 15;16(3):1036. doi: 10.62347/SBSI1515. eCollection 2024.ABSTRACT[This corrects the article on p. 2656 in vol. 15, PMID: 37193155.].PMID:38586108 | PMC:PMC10994810 | DOI:10.62347/SBSI1515 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Zhengchang He Shaoxian Shen Yuyao Yi Lingli Ren Huan Tao Fujue Wang Yongqian Jia Source Type: research
Exploring the molecular mechanisms between lymphoma and myelofibrosis
Am J Transl Res. 2024 Mar 15;16(3):730-737. doi: 10.62347/NWJO7078. eCollection 2024.ABSTRACTLymphoma is a heterogeneous malignant tumor with an increasing annual incidence. As the lymphoma progresses, bone marrow (BM) invasion gradually appears. Myelofibrosis (MF) can accompany a variety of hematological malignancies, including lymphoma, and multiple myeloma. The prognosis of lymphoma patients with myelofibrosis is poor, and a fundamental reason is that there are few studies on the correlation and pathogenesis of the two diseases. In this review, we examine the potential pathogenesis and the correlation of the two disease...
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Jun-Nuan Wang Yan Li Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 8, 2024 Category: Nuclear Medicine Authors: Lars Kurch Regine Kluge Source Type: research
